Precision medicine approach for a rare liver cancer
Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma
This study is trying to find better ways to diagnose and treat a rare liver cancer by looking at its genes and using advanced technology to help patients get more personalized care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Inserm U955 Academic / other |
| Locations | 1 site (Créteil) |
| Trial ID | NCT06146127 on ClinicalTrials.gov |
What this trial studies
This project focuses on the characterization of combined hepatocellular-cholangiocarcinoma (cHCC-CCA), a rare and aggressive liver cancer. The study aims to identify actionable gene alterations and improve diagnostic methods through the use of immunohistochemical biomarkers and deep-learning models. By analyzing a multicentric series of 357 cHCC-CCA samples, the researchers will perform gene and RNA sequencing, digital pathology, and immunohistochemistry to create a morphomolecular classification of the tumor. This integrative approach seeks to enhance understanding of the disease and facilitate precision medicine for affected patients.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a histological diagnosis of combined hepatocellular-cholangiocarcinoma and available biological samples.
Not a fit: Patients with unequivocal histological features of liver cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and targeted therapies for patients with cHCC-CCA.
How similar studies have performed: While there have been studies on liver cancer, this specific approach to cHCC-CCA using precision medicine and deep learning is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: histological diagnosis of combined tumor biological sample available Exclusion Criteria: unequivocal histological features
Where this trial is running
Créteil
- Julien Calderaro — Créteil, France (Recruiting)
Study contacts
- Principal investigator: Julien Calderaro — Inserm/APHP
- Study coordinator: Julien Calderaro
- Email: julien.calderaro@aphp.fr
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.